Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
AIP to Take Avanos Medical Private in $1.27 B Deal
Private‑equity sponsor AIP announced a $1.27 billion cash offer to take Avanos Medical private. The deal values the med‑tech company at a premium to its 2025 revenue of $701.2 million and promises additional resources for its specialty‑nutrition and pain‑management portfolios.
Biogen's Stock Slumps as Biosimilars Hit MS Sales and Alzheimer Setbacks Loom
Biogen (BIIB) saw its stock slip after reporting modest revenue growth, heightened biosimilar competition in multiple sclerosis, and lingering commercial challenges for its Alzheimer’s drug Leqembi. The biotech’s 2025 revenue rose only 2% to $9.9 billion while adjusted EPS fell 7%,...
Aurora Cannabis Buys EU GMP Cultivator Safari Flower for $26.5 Million
Aurora Cannabis Inc. completed the purchase of Safari Flower Company for $26.5 million, adding EU GMP‑certified manufacturing capacity. The deal includes $15 million cash, a $2 million contingent payment and over 2.4 million Aurora shares, positioning the Canadian firm to capture more of Europe’s...
Re: Managing Resistant Hypertension . . . And Other Research
A retired physician, David Levine, wrote to BMJ questioning the reported cardiovascular event numbers in a recent LDL‑lowering study, noting that the intensive‑therapy arm was listed with 147 events versus 100 in the conventional arm. He suggests the figures may...
Smarter Oncology Management Needed as Costs Continue to Climb
At the AMCP 2026 meeting, experts warned that oncology has become the largest cost driver for health plans, with cancer drugs accounting for 50‑60% of total cancer spend. They highlighted that expanding FDA approvals, longer treatment courses, and combination regimens...
Spotlight On: Biosimilar Litigations - April 2026
The April 2026 Spotlight On: Biosimilar Litigations memo outlines which patent disputes are tracked in the sector. It clarifies that lawsuits between biosimilar applicants or manufacturers and reference‑product sponsors are included, while conflicts solely among reference sponsors or non‑practicing entities are...
UK Says It Has Hit Target on Commercial Trial Set-Up Times
The UK’s National Institute for Health and Care Research (NIHR) reported that average clinical‑trial set‑up time fell to 122 days in the six months to March, beating its 150‑day target set for March 2026. The reduction follows a suite of reforms,...
HIMSS Executive Connect Brings 'Life-Changing' New Perspectives
The HIMSS Executive Connect program gave Sophia Brown, RN and CEO of Strategic Informatics Solutions, a fresh view on collaborative problem‑solving across health‑tech firms. By convening leaders from diverse organizations, the initiative highlighted shared challenges in AI, business intelligence and...
High-Dose Folic Acid Slashes Birth Defect Risks
A large Nordic study of over 13,000 pregnancies shows that high‑dose folic acid taken at least one month before conception cuts the risk of major congenital anomalies in children of women using antiseizure medications by about 45%, an absolute reduction...
How The Trump Administration Is Blocking Access To Home Care
The Trump Administration is simultaneously touting consumer choice while tightening two levers that restrict home‑based care: aggressive immigration curbs that shrink the caregiver pool and sweeping Medicaid reforms that slash federal funding. Over the next decade, the budget bill will...
Psychologist Argues Against Legalizing Psychedelics for Therapy
I'm not a narc. But as a psychologist and past clinical researcher, I currently oppose the legalization of psychedelics for mental health. Here's why.
Nanoz Rolls Out AI‑powered 2 Mm Nanosensors for Health and Environmental Monitoring
Nanoz, a French deep‑tech company, announced the industrial launch of AI‑enabled nanosensors no larger than 2 mm. The devices combine metal‑oxide semiconductor gas detection with machine‑learning algorithms to identify disease biomarkers, cabin‑air hazards and urban pollutants, opening new markets in healthcare,...
Researchers Encode Full Hepatitis D Genome on IBM Quantum System One
Scientists from the Wellcome Sanger Institute, Oxford, Cambridge, Melbourne and Kyiv Academic University have loaded a complete Hepatitis D virus genome onto IBM Quantum System One’s 156‑qubit Heron processor. The milestone, achieved under the Wellcome Leap‑funded Q4Bio Challenge, demonstrates that...
DIGI Search Launches Full-Service Dental Web Platform Tied to NextGen TV Ads
DIGI Search announced a new full-service dental web management platform that integrates its proprietary NextGen TV advertising suite. The initiative aims to move dental practices away from fragmented social‑media ads toward high‑impact, household‑level TV placements, promising higher‑value case acquisition.
MeiraGTx Reacquires Gene Therapy Candidate Bota-Vec for X‑Linked Retinitis Pigmentosa
MeiraGTx Holdings plc announced it has signed an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec), its AAV‑RPGR gene‑therapy for X‑linked retinitis pigmentosa (XLRP). The company says the deal positions it to file Biologics License Applications...
The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the...
Kennedy’s appearance on The Joe Rogan Experience announced that roughly fourteen peptides could be re‑classified from FDA Category 2 back to Category 1, but no Federal Register rule has been issued yet. The announcement highlights a procedural path where nominators withdraw nominations,...
Another Win for Opportunistic Screening: AI Turns Head CT Scans Into Heart Assessments
Researchers at Harvard Medical School have trained deep‑learning models on nearly 100,000 head CT scans to predict cardiovascular disease (CVD) risk and estimate coronary artery calcium (CAC) scores. The AI‑derived CVD timing model outperformed the American Heart Association’s PREVENT risk...
Staging, ctDNA, and the Art of Personalizing Metastatic Breast Cancer Therapy: Hayley Knollman, MD
Hayley M. Knollman, MD, highlighted how estrogen‑receptor‑positive metastatic breast cancer still relies on conventional staging—blood work, imaging, and tissue biopsies—while emerging HER2‑low categories gain relevance only after disease spreads. She noted that circulating tumor DNA (ctDNA) and broad genomic panels are now...
AI Documentation Seen as a ‘Competitive Advantage’ in Hospice Regulatory Labyrinth
Hospices are turning to artificial‑intelligence documentation platforms to ease staffing shortages and meet mounting Medicare audit demands. Dr. Brian Haas, national medical director at Ascend Hospice, argues that precise, rapid documentation will become a measurable competitive advantage. While AI can...
![[April 2026] FDA Form 483 Response Guidance, Weight Loss Device Framework + AI-Driven Device Warning Letter](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://substackcdn.com/image/fetch/$s_!CHiL!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F59dae4d3-b9e4-442b-8b97-0a78fab4dc99_582x582.png)
[April 2026] FDA Form 483 Response Guidance, Weight Loss Device Framework + AI-Driven Device Warning Letter
The FDA released three pivotal documents in April 2026: a finalized guidance on responding to Form 483 observations, a structured benefit‑risk framework for weight‑loss devices, and a warning letter to an autonomous insulin‑delivery system. The Form 483 guidance offers the...
Utah Measles Outbreak Tops 600 Cases as Connecticut Leads Nation in Vaccination Rate
Utah is grappling with a severe measles outbreak that has surpassed 600 confirmed cases, with more than 400 reported since the start of 2026 and nearly 50 hospitalizations. About 85% of those infected are unvaccinated, despite roughly 90% overall MMR...
RFK Jr. Defends FDA, Makary Following Republican Questions
HHS Secretary Robert F. Kennedy Jr. took the podium before the House Energy & Commerce Committee on April 16, 2026 to defend the Food and Drug Administration and its commissioner, Marty Makary, after a line of Republican inquiries. Kennedy asserted that the FDA’s approval processes remain...
OpenAI Debuts GPT-Rosalind, a New Limited Access Model for Life Sciences, and Broader Codex Plugin on Github
OpenAI unveiled GPT‑Rosalind, a domain‑specific reasoning model built to accelerate life‑science research, alongside a Codex plugin that links the model to over 50 public multi‑omics databases. The model demonstrated top‑tier performance on benchmarks such as BixBench and LABBench2, surpassing GPT‑5.4...
Closing the Execution Reliability Gap in Health Care Systems
Katherine Owen highlights the "execution reliability gap"—the disconnect between well‑designed discharge plans and patients' ability to follow them at home. While hospitals excel at diagnosis and risk prediction, they often lack the infrastructure to ensure patients translate instructions into daily...
Flawed Study Groups Failed and Successful Alzheimer Drugs Together
This new analysis of Alzheimer's drugs is such a good example of why we can't make any headway as a society. There is probably a good debate to be had on whether the risks and costs of the two approved beta...
Spotlight On: Humira® (Adalimumab) / Amjevita™ (Adalimumab-Atto) / Cyltezo® (Adalimumab-Adbm) / Hyrimoz™ (Adalimumab-Adaz) / Hadlima™ (Adalimumab-Bwwd) / Abrilada™ (Adalimumab-Afzb) /...
The April 2026 update spotlights the extensive patent‑litigation landscape surrounding adalimumab and its biosimilar portfolio, including Humira® and ten newer biosimilars such as Amjevita™ and Cyltezo®. It explains how claims are tallied across Inter‑Partes Review (IPR) proceedings and federal lawsuits, noting...
For Regrowing Human Limbs, This Salamander Gene Could Hold the Key
Scientists identified SP6 and SP8 as conserved genes that drive limb regeneration in axolotls, zebrafish and mice, and demonstrated that a viral gene‑therapy delivering FGF8 can partially rescue digit regrowth in mice lacking these genes. The work, published in PNAS,...
FDA Signals Potential Expansion of Testosterone Therapy to Treat Low Libido in Idiopathic Hypogonadism
The FDA announced it will entertain supplemental new drug applications to add low libido in men with idiopathic hypogonadism as an approved indication for existing testosterone replacement therapy (TRT) products. The move follows a December 2025 expert panel review of...
Clinical Trial of a Prion Disease Drug Candidate Begins Enrolling Participants
Broad Institute and UMass Chan have launched the first human trial of a prion disease therapy, a divalent small interfering RNA designed to silence the prion protein gene. The phase 1 PRiSM study will enroll 15 symptomatic patients to assess...
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
Eli Lilly has released topline safety results from its Phase III Achieve‑4 trial for Foundayo, addressing FDA‑requested evidence on cardiovascular, liver and gastric safety. The FDA’s post‑approval letter, issued on the day of approval, demanded trial data rather than observational studies. Concurrently,...
FDA Scientists Working in Satellite Laboratories Across U.S. Help Prevent Harmful Drugs From Reaching Americans
The FDA’s National Forensic Chemistry Center runs satellite laboratories inside high‑volume international mail hubs in Chicago, New York, Los Angeles, Miami and Honolulu. These compact labs use spectroscopy and mass spectrometry to screen incoming packages for counterfeit, unsafe or novel drug compounds...
How Healthcare Organizations Can Go From Technical Debt to a Hybrid Infrastructure That Supports Innovation
Healthcare providers are wrestling with aging IT assets that create security risks and impede patient care. Executives at the Medical College of Wisconsin and Children’s Mercy argue that moving suitable applications to the cloud transforms technical debt into a strategic...
RSV Vaccines Work to Prevent Hospitalization
Recent clinical data show that newly approved respiratory syncytial virus (RSV) vaccines dramatically cut hospital admissions. In infants, the vaccine lowered hospitalization risk by roughly 70%, while older adults experienced a 50% reduction in severe cases. The FDA has accelerated...
Arterial Plaque Impacts Women Differently From Men
A new analysis of the PROMISE trial shows that while women develop coronary plaque less frequently than men, they experience serious cardiac events with a lower plaque burden. The study compared imaging data from thousands of chest‑pain patients and found...
Choosing the Right Healthcare Provider
Choosing the right healthcare provider is a critical skill that influences health outcomes, costs, and patient satisfaction. The article emphasizes that navigating a fragmented system—ranging from preventive care to chronic disease management—requires understanding provider specialties, training, and care models. It...
Aerobic Activity Is Best for Knee Osteoarthritis
X‑rays reveal that roughly 30% of adults over age 45 show signs of knee osteoarthritis, and half of those individuals already experience pain. Recent research highlighted in Tufts Health & Nutrition indicates aerobic activity, such as brisk walking or cycling,...
Roche to Start Phase III Trial to Broaden Access to Elevidys in Duchenne Muscular Dystrophy
Roche announced a global, pivotal Phase III trial of Elevidys, its gene‑therapy for Duchenne muscular dystrophy, targeting roughly 100 early‑ambulatory boys. The 72‑week, placebo‑controlled study will assess change in time‑to‑rise‑from‑floor velocity as the primary efficacy endpoint. Results are intended to bolster...
Judith Suminwa Leads Strategic Talks at World Bank–IMF Spring Meetings
DR Congo Prime Minister Judith Suminwa Tuluka attended the World Bank‑IMF Spring Meetings in Washington from April 13‑18, 2026. She held high‑level talks on the country’s macroeconomic outlook and the upcoming third IMF program review, which could unlock additional budget support....
Study Data Technical Conformance Guide - Technical Specifications Document
The FDA has issued the final Study Data Technical Conformance Guide (Docket FDA-2014-D-0092), outlining technical specifications for electronic study data submissions. The guidance clarifies the agency’s expectations but remains non‑binding, allowing sponsors to use alternative approaches that meet regulatory requirements....
Best Cities for Top-Quality Eye Care
Do anyone tell me …. Which city would be best for eye treatment …. In terms if hospitals /doctors ….
Erika Schwartz Nominated to Lead CDC After Vacancy
#CDC has been without a director for most of Trump 2.0. A new nominee was put forward today, Erika Schwartz, a former deputy surgeon general. (Nomination was scooped earlier this week by @ddiamond & @bylenasun ). Let's see what happens....
Even Small Alcohol Increases Heart Rate, Lowers HRV
"Researchers looked at over 5 million days of data and found that even a modest amount of alcohol caused resting heart rates to climb and heart rate variability (a sign of how well your body handles stress) to drop." https://t.co/qg4663hHCS
Inside Epic's Confidential Vendor Deal Reveals Innovation Barriers
Second Opinion just published its first scoop: And it's a look inside Epic's confidential vendor services agreement. A source shared it with @RuthReader to give us a sense of why it's so hard out there for healthcare innovators. View in...
RFK Jr. Defends FDA Chief Amid Industry Backlash
RFK Jr. defends FDA, Makary following Republican questions - also defends the $REPL CRL: "Marty made the correct decision to not approve that drug. But everybody goes after him because the industry is so powerful." https://t.co/CuEeNFCYpp
OpenAI Debuts GPT‑Rosalind, Entering Biopharma After Anthropic
NEW: OpenAI is the latest tech giant to move into biopharma, launching Thursday GPT-Rosalind, a life sciences-tailored version of its LLM Trails behind the very similar launch of Anthropic's Claude for Life Sciences by ~5 months. More here: https://t.co/zkXDwY0BBI
RFK Jr. Hearing Reveals Changing Health Care Politics
RFK Jr.'s first in a marathon series of hearings offers a window into a shifting politics of health care — for the Trump administration and Democrats alike w/ @ChelseaCirruzzo https://t.co/uZQqM1ximT
High‑Resolution TORC2 Structure Opens Path to Age‑Related Therapies
Activating TORC2 holds potential in medicine for treating age-related memory & hearing loss. New study out today @MolecularCell reveals the structure of TORC2 in highest-ever resolution - which is good news for drug developers & all of us who age...
Drug Discovery Expands Beyond AI to New Frontiers
The marked expansion of paths and methods for new drug development including and beyond AI @Joseph_C_Wu @james_y_zou @WuXuekun @ScienceMagazine https://t.co/hTJ4Rt181n https://t.co/H3U5BNR1ER
Prediction Markets Threaten Public Health, Says Science Magazine
Prediction markets like @Polymarket are a threat for public health, asserted in a @ScienceMagazine essay https://t.co/Kk2OOVrxHy https://t.co/1pGA9aiBAh
Hygiene Breakthroughs Face Ridicule Before Saving Lives
Soap & disinfectants have saved more lives than any therapy Mother deaths before Semmelweis: ~10–15% After Semmelweis (1847):~1–2% Doctors laughed at him. He went to asylum & died from a beating Breakthroughs are ridiculed until they become part of everyday life